Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chemical change may provide cancer prognosis:

This article was originally published in Clinica

Executive Summary

Measuring the degree of a chemical change in tumour DNA may help predict the severity of the cancer, according to a US study published in Cancer Research (October 1). Normal cells methylate DNA to switch genes off. Researchers at Ohio State University tested 47 breast tissue samples and found that cancerous tissue had much higher levels of methylation on certain gene sites than normal tissue. The findings also suggested that the degree of methylation might correlate with the seriousness of the tumour. The team is now working to compare methylation patterns in leukaemia, ovarian and lung cancer with disease severity.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT063894

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel